Outcomes and toxicity of oral Fosfestrol in metastatic castration-resistant prostate cancer—a real-world experience

• Published in: Ecancermedicalscience 2023-08, Vol.17, p.1589-1589
• Main Authors: Devi R, Nandini, Kumar Shenoy VP, Praveen, Ismail, Irshad, Avaronnan, Manuprasad
• Format: Article
• Language: English
• Subjects: Androgens; Cytotoxicity; Medical prognosis; Metastasis; Multivariate analysis; Oncology; Prostate cancer; Testosterone; Toxicity
• ISSN: 1754-6605; 1754-6605
• DOI: 10.3332/ecancer.2023.1589

IntroductionAlthough there are multiple drugs approved for the treatment of metastatic castration-resistant prostate cancer (CRPC), the cost can be a limiting factor in using them in a resource-limited setting. Therefore, less expensive alternatives are the need of the hour. We have been using Fosfestrol which is a cheap and orally administered oestrogen analogue in metastatic CRPC. We carried out a retrospective study to analyse its efficacy and toxicity.ResultsA total of 65 patients received Fosfestrol during 2015–2020. The median age was 65 years (range 50–83 years). Thirty-four patients (53%) had other medical comorbidities. Skeletal-only metastasis was the commonest pattern of metastasis (n = 41, 64%) followed by skeletal with nodal metastasis (n = 15, 23%). The majority of the patients had undergone upfront surgical castration (n = 60, 93%). All the patients had adenocarcinoma and 38 patients (58%) had a high Gleason’s score. Forty-one patients (63%) had a prostate-specific antigen (PSA) response (decrease of ≥50% in the PSA concentration from the pre-treatment baseline PSA value) and 54 patients (83%) had a symptomatic response. At the end of a median follow-up of 16 months, the median progression-free survival (PFS) was 8.3 months (CI 4.7–11.8) and the median overall survival (OS) was 27.5 months (CI 25.4–29.5). PSA response and prior treatment with abiraterone acetate were found to have a significant association with survival outcomes. Patients with PSA response had better median PFS and OS; while patients who have received prior abiraterone acetate therapy had worse survival outcomes. Twenty-nine patients (45%) received some form of subsequent treatment after stopping Fosfestrol. The most common oxicity observed was thrombosis (n = 9, 13%) followed by gynecomastia (n = 4, 6%).ConclusionWe conclude that oral Fosfestrol is a cheap and effective agent in the armamentarium against metastatic CRPC and warrants further studies in a clinical trial setting.